COVIRAN vaccine starts efficacy tests after proving safe
Yusef Jalali
Press TV, Tehran
Among the eight viable vaccine candidates in Iran, COVIRAN is inching closer to the market.
Produced by the Headquarters for executing Imam Khomeini's Order, COVIRAN kickstarted the second and third human trial phases at the same time on Monday.
Volunteers say they feel proud to be part of this great endeavor for humanity.
The vaccine wrapped up its first phase a month ago.
Phase 1 sought to test whether or not the vaccine is safe to be injected to everyone.
Now the second phase will assess the efficacy of the vaccine against the virus.
As the virus keeps mutating to more lethal forms, COVIRAN experts are certain that the Iranian vaccine is effective at least against the British version of the virus.
Iran is working on seven other homegrown vaccines, including COV-PARS, which is now undergoing the first phase of the human trials.
This as the country has already started mass vaccination, mainly using Russia's Sputnik V.
The question of how much immunity COVIRAN will make will only be answered once the second stage is over. Meanwhile, developers say they have already kicked off mass production of the vaccine to catch up with the country's plan to base its national vaccination program on a domestic vaccine.
Public uproar in US against Israeli regime
Rome, Milan host new protests in solidarity with Palestinians
Iran honors top Science Olympiad medalists
‘All wars have rules. All of those rules have been broken’ by Israel
VIDEO | Report flags India’s violation of rights of Rohingya detainees
Turkey's foreign minister meets Syria's de facto leader in Damascus
'Next to impossible' to rescue patients from Gaza's Kamal Adwan Hospital: Director
VIDEO | Vietnam current prosperity
Report blames gasoil exports for shortage at Iranian power plants
VIDEO | Hind Rajab Foundation names Israeli war criminals vacationing after Gaza genocide
VIDEO | Australians rally for Gaza ahead of Christmas festivities
PressTV NEWSLETTER
now
This makes it easy to access the Press TV website
